KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Receivables (2017 - 2025)

Aquestive Therapeutics has reported Receivables over the past 9 years, most recently at $27.5 million for Q4 2025.

  • Quarterly results put Receivables at $27.5 million for Q4 2025, up 180.26% from a year ago — trailing twelve months through Dec 2025 was $27.5 million (up 180.26% YoY), and the annual figure for FY2025 was $27.5 million, up 180.26%.
  • Receivables for Q4 2025 was $27.5 million at Aquestive Therapeutics, up from $14.1 million in the prior quarter.
  • Over the last five years, Receivables for AQST hit a ceiling of $27.5 million in Q4 2025 and a floor of $6.8 million in Q4 2022.
  • Median Receivables over the past 5 years was $11.8 million (2023), compared with a mean of $13.5 million.
  • Biggest five-year swings in Receivables: tumbled 56.35% in 2022 and later skyrocketed 180.26% in 2025.
  • Aquestive Therapeutics' Receivables stood at $15.7 million in 2021, then tumbled by 56.35% to $6.8 million in 2022, then soared by 66.39% to $11.4 million in 2023, then fell by 13.78% to $9.8 million in 2024, then skyrocketed by 180.26% to $27.5 million in 2025.
  • The last three reported values for Receivables were $27.5 million (Q4 2025), $14.1 million (Q3 2025), and $14.1 million (Q2 2025) per Business Quant data.